



Interhospital Conference Case 2

Nathathai Pratumchart, MD

Ploysyne Rattanakaemakorn, MD




A 24-year-old female

**Generalized,
ill-defined depressed
areas on trunk and
extremities for 2 years**



Present illness

May 2015



**Dx: SLE (Malar rash,
polymyalgia, alopecia,
ANA 1:1280)**

Rx:

prednisolone 60 mg/day
HCQ 200 mg/day

Present illness

May 2015

Sep 2015

Dx: SLE (Malar rash, polymyalgia, alopecia, ANA 1:1280)

Rx:

prednisolone 60 mg/day
HCQ 200 mg/day

Disease stable

Rx:

↓ prednisolone
2.5 mg/day

Present illness

May 2015

Sep 2015

Nov 2017

Dx: SLE (Malar rash, polymyalgia, alopecia, ANA 1:1280)

Rx:
prednisolone 60 mg/day
HCQ 200 mg/day

Disease stable

Rx:
↓ prednisolone
2.5 mg/day

Developed ill-defined depressed areas on upper extremities

Rx: observe

Present illness

May 2015

Sep 2015

Nov 2017

Jan 2020

Dx: SLE (Malar rash, polymyalgia, alopecia, ANA 1:1280)

Rx:

prednisolone 60 mg/day
HCQ 200 mg/day

Disease stable

Rx:

↓ prednisolone
2.5 mg/day

Developed ill-defined depressed areas on upper extremities

Rx: observe

**Dermatological
consultation**

**Progressive lesions on
trunk and extremities**

Past history

- Underlying disease
 - ◆ Stable SLE
- Current medications
 - ◆ Prednisolone 2.5 mg/day
 - ◆ Folic acid 5 mg/day

Physical examination

- Vital signs: BT 36 °C BP 120/80 mmHg
 HR 70 bpm RR 20 /min
- BW 60 kg, Ht. 165 cm (BMI 23 Kg/m²)
- HEENT: no pale conjunctivae, anicteric sclerae
- Heart & lungs: WNL
- Abdomen: no hepatosplenomegaly


Dermatological examination




Bilateral, ill-defined, depressed areas
on both arms and trunk



Bilateral, ill-defined, depressed areas
on both arms and trunk




Ill-defined, depressed areas on abdomen



Ill-defined, depressed areas on abdomen



Bilateral, ill-defined, depressed areas on buttock



Bilateral, ill-defined, depressed areas on buttock



Bilateral, ill-defined, depressed areas
on both thighs and legs



Bilateral, ill-defined, depressed areas
on both thighs and legs

Problem list

1. Acquired, generalized, depressed areas
for 2 years
2. Stable SLE

Differential diagnosis

Acquired, generalized, depressed lesions

Inflammation

- **Lipodystrophy syndromes**
- **Lupus panniculitis**
- **Subcutaneous morphea**


Infection

- **Infectious panniculitis**




Histopathology


H&E
40X



H&E
40X



H&E
100X



Lipodystrophy syndromes

Congenital

Acquired


Lipodystrophy syndromes

Congenital

Acquired

Localized

Trauma
Injection
Pressure



Lipodystrophy syndromes

Congenital


Acquired

Localized

Generalized

Partial

- Lipodystrophy, often with muscular prominence
- Lipohypertrophy




MRI of forearms



- Mild inflammatory process at subcutaneous tissue of both forearms

MRI of forearms



- No muscular dystrophy

Investigation

- Liver and renal function tests
- Lipid profiles
- Serum glucose
- Serum uric acid

} WNL

Acquired generalized lipodystrophy or Lawrence syndrome

Epidemiology

- Rare condition ~80 cases until now
- Childhood to adolescence
- F:M 3:1

Etiology and pathogenesis

- Unknown
- 25% have a preceding panniculitis
- Localized → generalized fat loss

Locations of fat loss

Common

Large areas of face,
trunk, and extremity




Uncommon

Palms, soles, and
intraabdominal regions



Not found

Bone marrow and
retroorbital fat



Subtypes

- Type 1: panniculitic variant (25%)
- Type 2: autoimmune variant (25%)
- Type 3: idiopathic (50%)

Complications

- Severe hepatic steatosis and fibrosis
 - ◆ A significant cause of death
- Diabetes mellitus
 - ◆ Latency period ~ 4 years
- Hypertriglyceridemia
- Proteinuric nephropathy

Prognosis

- Severe metabolic complications
- ↑ Risk of peripheral T-cell lymphoma
- Panniculitis-associated variety
 - ◆ Severe fat loss
 - ◆ Metabolic complications

Less

Suggested investigation

- Serum chemistry profiles
 - ◆ Glucose
 - ◆ Lipids
 - ◆ Liver enzymes
 - ◆ Uric acid
- Insulin resistance

Suggested investigation

- Serum leptin
 - ◆ Low level
 - ◆ Guide treatment decisions
(metreleptin replacement therapy)
- Skin biopsy

Special tests

- Skinfold thickness
 - ◆ Anthropometry
- Body fat distribution
 - ◆ Dual X-ray absorptiometry
 - ◆ MRI

Management

- No specific treatment
 1. Reassure
 2. Supportive treatments
 - ◆ Cosmetic surgery
 3. Management and surveillance of complications

Our case

- 3 subtypes
 - ◆ Type 1: panniculitic (25%)
 - ◆ Type 2: autoimmune (25%)
 - ◆ Type 3: idiopathic (50%)

Type 2: autoimmune variety

Organ-specific autoimmunity

Type 1 diabetes mellitus

Autoimmune hepatitis

Systemic autoimmune diseases

Juvenile dermatomyositis

Juvenile idiopathic arthritis

Sjogren syndrome

Case summary

- A 24 y/o female with SLE
- **CC:** Generalized depressed areas on trunk and extremities for 2 years
- **Dx:** Acquired generalized lipodystrophy or Lawrence syndrome
- **Treatment:** Denied lipofilling
- **Plan:** Surveillance of complications



Take home message

**Acquired generalized lipodystrophy
(Lawrence syndrome)**

Associated with autoimmune diseases

Surveillance of metabolic complication is suggested